Grifols and Beckman Coulter Enter into an Exclusive Distribution Agreement

Jun 12, 2017 - (Newswire)

- Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), one of the world's leading producers of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, and Beckman Coulter Inc., a leading provider of innovative, efficient and reliable diagnostics solutions, have entered into an exclusive, long-term agreement for the global distribution of Grifols' hemostasis instruments, reagents and consumables.

"Grifols continues to execute its strategy in growing the Specialty Diagnostics line. Our hemostasis product line complements Beckman Coulter's broad portfolio of products and services for the core laboratory," said Carsten Schroeder, Grifols President of Diagnostic Commercial Operations.

"Beckman Coulter's long-term partnership with Grifols expands our extensive diagnostic product offering and further supports our position as a partner of choice with hospitals and clinical laboratories across the world," stated Arnd Kaldowski, President of Beckman Coulter Diagnostics.

"Grifols' hemostasis product line, focused on reliability and efficiency, combined with our global distribution network, automation leadership and clinical informatics solutions for the core laboratory, provide our customers with even more solutions to deliver better patient care," added Kevin Chance, President of Products and Services for Beckman Coulter Diagnostics.

"We are extremely excited about the collaboration with Beckman Coulter. The agreement leverages Grifols' strength in manufacturing reliable instruments and reagents with that of Beckman Coulter's commercial strength," added Oriol Duñach, Grifols President of Diagnostic Industrial Division.

Beckman Coulter and Grifols anticipate first commercializing systems under this distribution agreement in Europe in early 2018.

About Grifols
Grifols is a global healthcare company with more than a 75-year legacy of improving people's health and well-being through the development of protein therapies, hospital pharmacy products and diagnostic technology for clinical use.

The company is present in more than 100 countries worldwide, with headquarters located in Barcelona, Spain. Grifols is a leader in plasma collection with a network of more than 170 plasma donation centers in the U.S., and is a leading producer of plasma-derived medicines. As a recognized leader in transfusion medicine, Grifols offers a comprehensive range of transfusion medicine, hemostasis, and immunoassay solutions for clinical laboratories, blood banks, and transfusion centers.

In 2016, sales exceeded 4,000 million euros with approximately 15,000 employees. Grifols demonstrates its commitment to advancing healthcare by allocating a significant portion of its annual income to R&D.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE: GRF). Its non-voting class B shares are listed on the Mercado Continuo (MCE: GRF.P) and on the U.S. NASDAQ via ADRs (NASDAQ: GRFS). For more information about Grifols, visit www.grifols.com.

About Beckman Coulter Inc.
Beckman Coulter Diagnostics helps healthcare and laboratory professionals provide better patient care by delivering the accurate diagnostic information they need, when they need it. For more than 80 years, Beckman Coulter has been the partner of choice for healthcare organizations. The company's scalable instruments, comprehensive diagnostic tests and business management services are trusted by hospitals, laboratories and other critical care settings around the world. We share in our customers' mission toward continuous improvement and quality patient care because we believe when efficiency and clinical outcomes are improved, patients benefit and we can move healthcare forward for every person. For more information, visit www.beckmancoulter.com.

SOURCE Grifols

Related Links


Original Source: https://www.newswire.com/news/grifols-and-beckman-coulter-enter-into-an-exclusive-distribution-agreement

What Next?

Related Articles

Leave a Reply

Submit Comment